How to Tell if Your Hormone Clinic Is Actually Practicing Medicine

Two hormone clinics can have nearly identical websites. The same language about personalized care, the same testimonials, the same easy booking flow. The difference — whether a physician is genuinely involved, whether dosing reflects your biology, whether anyone is actually monitoring your care — lives underneath the surface. Here is how to read what is underneath.

Signs of a Real Medical Practice

The prescribing physician is identifiable and verifiable. There is a real name, a real credential, and a real medical license number you can look up on your state's licensing board. The physician is not described generically as "our clinical team" or "board-certified physicians." A physician whose identity is obscured behind a brand is not directly accountable to you in the way a named clinician is.

Comprehensive labs are required before prescribing. Not suggested. Required. A practice that asks for your medical history and prescribes on the basis of a questionnaire is not practicing individualized medicine. A practice that requires baseline hormone panels, reviews the results with you, and makes dosing decisions based on those results is.

You receive a clinical follow-up to review your results. Not a portal notification. A physician or clinician who explains what your labs show, how that maps to your symptoms, and why the recommended treatment is appropriate for you specifically. If no one is explaining your results, no one is practicing medicine for you.

Medication comes from a named, licensed pharmacy. Ask for the pharmacy name and verify it is licensed in your state. For compounded medications, verify that the compounding pharmacy holds an FDA-approved facility registration. If this information is unavailable or the practice is reluctant to provide it, that is a significant red flag.

Dosing decisions reference your lab results. Not a standard protocol. Your numbers. A physician explaining "your estradiol is at X, which is below the range we target for your symptom picture, so we are starting at Y dose" is practicing medicine. A physician saying "this is our standard starting protocol" without reference to your labs is not.

Signs of a Subscription Farm

"Get approved in minutes" or "No labs required." Approval speed and lab elimination are commercial features, not clinical ones. They exist to reduce friction in the sign-up flow, not to improve patient care.

Identical doses for all patients. If you learn that everyone in a program starts at the same dose regardless of their labs, age, weight, or symptom profile, the dosing is not individualized — it is standardized. Standardized dosing is efficient to administer and clinically inadequate.

Monthly auto-renewal with no required clinical review. A program that continues indefinitely without a scheduled clinical check-in — without someone reviewing whether the treatment is working, whether the dose is still appropriate, whether anything has changed — is a subscription. It is not ongoing care.

IHA's Clinical Standard

IHA's BHRT and GLP-1 programs are structured around the markers of a real medical practice. Named, licensed physicians making prescribing decisions. Comprehensive labs before treatment begins. Dosing individualized to your results. Scheduled monitoring at three and six months. A clinical team that can be reached when something changes. Physician-directed care is the model — not as a marketing phrase, but as the operational reality of how every patient is managed.

The markers described above are not aspirational standards. They are the minimum that "medical practice" actually requires. Applying them to evaluate a clinic you are considering takes less than thirty minutes — and the picture that emerges will tell you clearly whether you are looking at a medical practice or a subscription service that has adopted medical language.

How to Verify What You're Being Told

The markers described above are only useful if you can actually verify them. Here is how to do that for each critical marker.

Physician license verification: Every state has a medical licensing board with a publicly searchable database. In New Hampshire, this is the New Hampshire Board of Medicine at nh.gov/medicine. Enter the physician's name and confirm that their license is active, unrestricted, and valid for the state in which they are prescribing. This takes two minutes and is unambiguous. If a practice cannot or will not tell you the prescribing physician's name, this verification is not possible — which is itself the finding.

Pharmacy verification: For compounded hormones, the FDA maintains a database of registered outsourcing facilities (503B pharmacies) at fda.gov. For standard licensed pharmacies, the National Association of Boards of Pharmacy (NABP) maintains the .pharmacy domain verification program. Ask for the pharmacy name and its state license number, and look it up. A legitimate pharmacy will not object to this request.

Lab protocol verification: Ask for a copy of the lab requisition that will be used before treatment begins. It should include estradiol, progesterone, FSH, testosterone (total and free), SHBG, and DHEA-S at minimum. If the requisition is for fewer markers, ask why — and if the answer is that comprehensive labs are not required, you have learned something important about the practice's clinical standard.

The Practical Test: Call and Ask

The single most revealing evaluation you can do is a phone call. Call the practice and say: "I'd like to speak with the physician who would be managing my care." Then listen to what happens. A medical practice with real physician involvement will have a process for this — a scheduled call, a message that is returned, a patient coordinator who can confirm the physician's name and schedule a consultation. A subscription service will route you to a call center, put you in a chat window with a non-clinical staff member, or tell you that physician contact is available only after you subscribe.

The experience of trying to reach the physician is the most accurate preview of what ongoing care will look like. A physician who is not accessible before you sign up will not be accessible when you have a clinical question after you start. A practice that makes physician contact easy before the transaction is demonstrating that physician availability is a core feature of their model — not a premium add-on that requires escalation.

IHA's Commitment to These Standards

Every marker described in this post applies to IHA's clinical program. The prescribing physician is named, licensed, and verifiable. Comprehensive labs are required before any prescribing decision is made. Dosing is documented with reference to the patient's specific lab results. Monitoring at three and six months is a standard protocol component, not an optional upgrade. Medication comes from named, licensed pharmacies. Clinical staff — not a customer service queue — manages clinical questions.

These are not aspirational standards. They describe how IHA operates as a matter of clinical principle. Physician-directed care is not a marketing phrase here — it is the operational description of every patient's experience from the first consultation through ongoing treatment. BHRT and GLP-1 therapy are available through a clinical model that meets the standards described above — and that can demonstrate meeting them to any patient who applies the evaluation framework in this post. That is the appropriate standard for any practice claiming to provide medical care, and it is the standard to which IHA holds itself.

The Pattern of Red Flags Across Platforms

Commercial hormone and weight loss platforms that fail a careful clinical evaluation do not typically fail in idiosyncratic ways. They fail in predictable patterns that reflect the business logic driving them — and each pattern corresponds to a specific clinical risk that is worth understanding in concrete terms rather than as an abstract concern about quality.

The questionnaire-only intake is the most pervasive red flag and the most consequential. Platforms that replace a physician conversation with a symptom questionnaire and a medical history form are not conducting a clinical assessment — they are conducting a screening process designed to exclude the most obvious contraindications while approving the majority of applicants. The physician, if one is involved at all, reviews a completed form rather than speaking with the patient. This matters clinically because a questionnaire cannot do what a physician conversation can: follow up on ambiguous answers, recognize inconsistencies between symptoms and history, identify the unstated concern that a patient mentioned in passing as more significant than the presenting complaint. A woman who notes a family history of breast cancer and is not asked follow-up questions about her personal history, current screening status, or the type of breast cancer in her family has not been evaluated — she has been form-processed. The clinical consequence of this gap is that hormone therapy may be initiated in women for whom a complete clinical conversation would have identified a reason for caution or referral.

The lab-optional model is a related failure presented, in commercial platform marketing, as a feature: "no labs required," "start treatment today," "we don't make you wait for bloodwork." The actual clinical meaning of this presentation is that the prescribing decision is being made without the information required to make it safely. The most direct clinical example is the endometrial hyperplasia risk of estrogen without progesterone monitoring. A woman prescribed transdermal estradiol without a clinical assessment of whether she needs progesterone co-administration — which cannot be determined without knowing her hormonal status, uterine status, and symptom profile — may be receiving estrogen that stimulates endometrial proliferation without the progesterone-mediated secretory transformation that prevents hyperplastic change. Endometrial hyperplasia is a precursor to endometrial cancer. It is a preventable condition when treatment is managed with appropriate monitoring. Platforms that eliminate baseline labs eliminate the ability to assess this risk before it becomes clinically relevant.

The absence of a named physician in patient documentation is a third consistent pattern. Commercial platforms frequently list a Medical Director or clinical oversight team in their legal documentation without that individual having any direct involvement in individual prescribing decisions. The prescriptions are generated through a workflow that a physician nominally supervises but does not actually review on a case-by-case basis. The clinical implication is that the legal fiction of physician oversight does not correspond to actual physician judgment applied to a specific patient. When something goes wrong — a drug interaction, a contraindication that was present but not evaluated, a dose that was inappropriate for the patient's clinical picture — the patient has no recourse to a physician who actually made the decision, because no such physician exists in the chain of care.

The customer service call center handling clinical questions is the operational manifestation of the above. When a patient on a subscription hormone platform calls to report that her hair is thinning, her blood pressure has increased, or she is having irregular bleeding, she reaches a customer service representative rather than a clinical staff member. The representative may be trained to document the concern and escalate it, or may be trained to reassure and retain — the incentive structure of a commercial platform does not consistently favor clinical conservatism. The testosterone ceiling risk without follow-up labs is a specific example: a woman who is being prescribed testosterone cream without follow-up testing of her testosterone levels may be accumulating supraphysiologic levels that produce androgenic side effects — hair loss, acne, voice changes — that a clinical follow-up would have caught at the three-month mark. Without that follow-up lab, the side effects may persist for months before the patient connects them to the treatment.

The clinical standard that makes each of these patterns avoidable is not complicated: a named physician, a complete baseline lab panel, a defined follow-up schedule, and a clinical communication pathway for concerns. These are not aspirational standards — they are the minimum components of competent medical practice. The posts on prescription farms and questions to ask any clinic cover the structural analysis and evaluation framework in more detail. For women who want to understand what a clinical intake that does not exhibit these patterns looks like in practice, connecting with IHA provides that comparison directly — the difference between a real clinical intake and a questionnaire screen is apparent immediately in the quality of the questions you are asked and the clinical reasoning behind the process.

There is one additional pattern worth naming that does not fit neatly into any single checklist item but is consistently present in commercial platforms that fail the clinical evaluation: the absence of a defined escalation protocol when something goes wrong. A real clinical practice has a documented process for what happens when a patient reports a concerning symptom — a new irregular bleeding pattern on hormone therapy, a persistent headache, a cardiovascular symptom, an unexpected change in mood. That process involves a clinical staff member triaging the concern, a physician reviewing anything that meets a defined clinical threshold, and a defined response timeline. Commercial subscription platforms typically have no such process; they have a customer service tier that documents complaints and may escalate to a refill hold or a generic safety message. The absence of an escalation protocol is not a minor administrative gap. It is the operational failure that allows a patient experiencing a genuine adverse event to remain on a medication that should have been paused pending clinical evaluation. When you ask a clinic what happens if you call with a clinical concern between appointments, the answer should describe a clinical pathway — specific, tiered, with physician involvement at defined thresholds. An answer that describes a callback from a patient coordinator or a note logged in your account is telling you that clinical escalation does not exist. That is information you need before you start, not after something goes wrong.

Red Flags Versus Green Lights: Building Your Evaluation Criteria

The most useful summary of the red-flag pattern is this: any clinic that makes the approval of your requested treatment the path of least resistance is prioritizing transaction over clinical judgment. A real medical practice makes the correct clinical decision the path of least resistance — which sometimes means approval, and sometimes means modification, and sometimes means a different treatment entirely.

The green lights that indicate you are dealing with a medical practice rather than a subscription service are the mirror image: a specific physician you can name and whose credentials you can verify; a prescribing decision that explicitly references your lab results rather than your questionnaire score; a monitoring schedule that is built into the program structure rather than offered as an option; and a response to your between-appointment clinical questions that comes from a clinician rather than a ticketing system. IHA's BHRT and GLP-1 programs are built to pass every one of these tests. The initial consultation is where you can verify them directly — the same due diligence standard that should be applied to every provider in this space.